Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 469

1.

Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis.

Poteat T, Hanna DB, Rebeiro PF, Klein M, Silverberg MJ, Eron JJ, Horberg MA, Kitahata MM, Mathews WC, Mattocks K, Mayor A, Rich AJ, Reisner S, Thorne J, Moore RD, Jing Y, Althoff KN; North American AIDS Cohort Collaboration On Research and Design of the International Epidemiology Databases to Evaluate AIDS.

Clin Infect Dis. 2019 Apr 23. pii: ciz322. doi: 10.1093/cid/ciz322. [Epub ahead of print]

PMID:
31573601
2.

Female genital tract shedding of HIV-1 is rare in women with suppressed HIV-1 in plasma.

Nelson JAE, de Paris K, Ramirez C, Edmonds A, Mollan KR, Bay CP, Compliment K, Herold BC, Anastos K, Minkoff H, Kassaye S, Seidman DL, French AL, Golub ET, Sheth AN, Ochsenbauer C, Swanstrom R, Eron JJ, Adimora AA.

AIDS. 2019 Sep 2. doi: 10.1097/QAD.0000000000002373. [Epub ahead of print]

PMID:
31483374
3.

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.

Huhn GD, Eron JJ, Girard PM, Orkin C, Molina JM, DeJesus E, Petrovic R, Luo D, Van Landuyt E, Lathouwers E, Nettles RE, Brown K, Wong EY.

AIDS Res Ther. 2019 Aug 29;16(1):23. doi: 10.1186/s12981-019-0235-1.

4.

Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS).

Feinstein MJ, Nance RM, Delaney JAC, Heckbert SR, Budoff MJ, Drozd DR, Burkholder GA, Willig JH, Mugavero MJ, Mathews WC, Moore RD, Eron JJ, Napravnik S, Hunt PW, Geng E, Hsue P, Peter I, Lober WB, Crothers K, Grunfeld C, Saag MS, Kitahata MM, Lloyd-Jones DM, Crane HM.

BMC Med. 2019 Jul 31;17(1):149. doi: 10.1186/s12916-019-1385-7.

5.

Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART.

Bedimo RJ, Mar H, Bosch RJ, Drechsler H, Cyktor JC, Macatangay BJC, Lalama C, Rinaldo C Jr, Collier A, Godfrey C, Hogg E, Hensel C, Eron JJ, Mcmahon DK, Mellors JW, Tebas P, Gandhi RT; A5321 Study Team.

J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):e27-e31. doi: 10.1097/QAI.0000000000002124.

PMID:
31335587
6.

Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.

Spudich S, Robertson KR, Bosch RJ, Gandhi RT, Cyktor JC, Mar H, Macatangay BJ, Lalama CM, Rinaldo C, Collier AC, Godfrey C, Eron JJ, McMahon D, Jacobs JL, Koontz D, Hogg E, Vecchio A, Mellors JW.

J Clin Invest. 2019 Jul 15;129(8):3339-3346. doi: 10.1172/JCI127413. eCollection 2019 Jul 15.

7.

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.

Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M; EMERALD study group.

Antiviral Res. 2019 Oct;170:104543. doi: 10.1016/j.antiviral.2019.104543. Epub 2019 Jul 4.

8.

Clones of infected cells arise early in HIV-infected individuals.

Coffin JM, Wells DW, Zerbato JM, Kuruc JD, Guo S, Luke BT, Eron JJ, Bale M, Spindler J, Simonetti FR, Hill S, Kearney MF, Maldarelli F, Wu X, Mellors JW, Hughes SH.

JCI Insight. 2019 Jun 20;4(12). pii: 128432. doi: 10.1172/jci.insight.128432. eCollection 2019 Jun 20.

9.

Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-week Results of AIDS Clinical Trials Group A5241 (OPTIONS).

Gandhi RT, Tashima KT, Smeaton LM, Vu V, Ritz J, Andrade A, Eron JJ, Hogg E, Fichtenbaum CJ; ACTG A5241 study team.

J Infect Dis. 2019 May 28. pii: jiz281. doi: 10.1093/infdis/jiz281. [Epub ahead of print]

PMID:
31135883
10.

Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.

Crane HM, Nance RM, Heckbert SR, Ritchings C, Rosenblatt L, Budoff M, Wood BR, Tirschwell DL, Kim HN, Mathews WC, Geng E, Moore RD, Hunt PW, Eron JJ, Burkholder GA, Drozd DR, Chow FC, Becker KJ, Zunt JR, Ho EL, Kalani R, Huffer A, Whitney BM, Saag MS, Kitahata MM, Delaney JAC.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):e141-e147. doi: 10.1097/QAI.0000000000002071.

11.

Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077.

Landovitz RJ, Zangeneh SZ, Chau G, Grinsztejn B, Eron JJ, Dawood H, Magnus M, Liu AY, Panchia R, Hosseinipour MC, Kofron R, Margolis DA, Rinehart A, Adeyeye A, Burns D, McCauley M, Cohen MS, Currier JS.

Clin Infect Dis. 2019 May 24. pii: ciz439. doi: 10.1093/cid/ciz439. [Epub ahead of print]

PMID:
31125395
12.

Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.

Nance RM, Vannappagari V, Smith K, Johannes CB, Calingaert B, Saltus CW, Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC, Crane HM.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):572-577. doi: 10.1097/QAI.0000000000002075.

13.

Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses.

Keating SM, Jones RB, Lalama CM, Bosch RJ, McMahon D, Hampton D, Cyktor J, Eron JJ, Mellors JW, Busch MP, Gandhi RT; ACTG 5321 Team.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):594-599. doi: 10.1097/QAI.0000000000002080.

PMID:
31045647
14.

HIV-1 Phylodynamics to Detect and Characterize Active Transmission Clusters in North Carolina.

Dennis AM, Hué S, Billock R, Levintow S, Sebastian J, Miller WC, Eron JJ.

J Infect Dis. 2019 Apr 27. pii: jiz176. doi: 10.1093/infdis/jiz176. [Epub ahead of print]

PMID:
31028702
15.

Impact of abstinence and of reducing illicit drug use without abstinence on HIV viral load.

Nance RM, Trejo MEP, Whitney BM, Delaney JAC, Altice F, Beckwith CG, Chander G, Chandler R, Christopoulous K, Cunningham C, Cunningham WE, Del Rio C, Donovan D, Eron JJ, Fredericksen RJ, Kahana S, Kitahata MM, Kronmal R, Kuo I, Kurth A, Mathews WC, Mayer KH, Moore RD, Mugavero MJ, Ouellet LJ, Quan VM, Saag MS, Simoni JM, Springer S, Strand L, Taxman F, Young JD, Crane HM.

Clin Infect Dis. 2019 Apr 17. pii: ciz299. doi: 10.1093/cid/ciz299. [Epub ahead of print]

PMID:
30994900
16.

Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia.

Hudson FP, Mulenga L, Westfall AO, Warrier R, Mweemba A, Saag MS, Stringer JS, Eron JJ, Chi BH.

Antivir Ther. 2019 Apr 12. doi: 10.3851/IMP3299. [Epub ahead of print]

PMID:
30977467
17.

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M.

AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223.

18.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD.

Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Review.

PMID:
30885693
19.

Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals.

Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage Iii GR, Bonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA.

Stat Med. 2019 Jun 15;38(13):2428-2446. doi: 10.1002/sim.8120. Epub 2019 Mar 18.

PMID:
30883859
20.

Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting.

Davy-Mendez T, Napravnik S, Zakharova O, Wohl DA, Farel CE, Eron JJ.

AIDS. 2019 Jun 1;33(7):1187-1195. doi: 10.1097/QAD.0000000000002194.

PMID:
30870198
21.

Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies.

Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, Lucas GM, Klein MB, Kitahata MM, Crane H, Silverberg MJ, Gill MJ, Mathews WC, Dubrow R, Horberg MA, Rabkin CS, Klein DB, Lo Re V, Sterling TR, Desir FA, Lichtenstein K, Willig J, Rachlis AR, Kirk GD, Anastos K, Palella FJ Jr, Thorne JE, Eron J, Jacobson LP, Napravnik S, Achenbach C, Mayor AM, Patel P, Buchacz K, Jing Y, Gange SJ; North American AIDS Cohort Collaboration on Research and Design.

Lancet HIV. 2019 Feb;6(2):e93-e104. doi: 10.1016/S2352-3018(18)30295-9. Epub 2019 Jan 22. Erratum in: Lancet HIV. 2019 Apr 2;:.

PMID:
30683625
22.

Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment.

Srinivas N, Joseph SB, Robertson K, Kincer LP, Menezes P, Adamson L, Schauer AP, Blake KH, White N, Sykes C, Luciw P, Eron JJ, Forrest A, Price RW, Spudich S, Swanstrom R, Kashuba ADM.

Clin Transl Sci. 2019 May;12(3):302-311. doi: 10.1111/cts.12620. Epub 2019 Feb 27.

23.

Randomized Controlled Pilot Study of Antiretrovirals and a Behavioral Intervention for Persons With Acute HIV Infection: Opportunity for Interrupting Transmission.

Miller WC, Rutstein SE, Phiri S, Kamanga G, Nsona D, Pasquale DK, Rucinski KB, Chen JS, Golin CE, Powers KA, Dennis AM, Hosseinipour MC, Eron JJ, Chege W, Hoffman IF, Pettifor AE.

Open Forum Infect Dis. 2018 Dec 19;6(1):ofy341. doi: 10.1093/ofid/ofy341. eCollection 2019 Jan.

24.

Estimating Human Immunodeficiency Virus (HIV) Prevention Effects in Low-incidence Settings.

Rudolph JE, Cole SR, Eron JJ, Kashuba AD, Adimora AA.

Epidemiology. 2019 May;30(3):358-364. doi: 10.1097/EDE.0000000000000966.

PMID:
30640216
25.

Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.

Joseph SB, Kincer LP, Bowman NM, Evans C, Vinikoor MJ, Lippincott CK, Gisslén M, Spudich S, Menezes P, Robertson K, Archin N, Kashuba A, Eron JJ, Price RW, Swanstrom R.

Clin Infect Dis. 2019 Sep 27;69(8):1345-1352. doi: 10.1093/cid/ciy1066.

PMID:
30561541
26.

Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights.

Buchanan AL, Hudgens MG, Cole SR, Mollan KR, Sax PE, Daar ES, Adimora AA, Eron JJ, Mugavero MJ.

J R Stat Soc Ser A Stat Soc. 2018 Oct;181(4):1193-1209. doi: 10.1111/rssa.12357. Epub 2018 Feb 26.

27.

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

Eron JJ Jr, Lelievre JD, Kalayjian R, Slim J, Wurapa AK, Stephens JL, McDonald C, Cua E, Wilkin A, Schmied B, McKellar M, Cox S, Majeed SR, Jiang S, Cheng A, Das M, SenGupta D.

Lancet HIV. 2018 Dec 13. pii: S2352-3018(18)30296-0. doi: 10.1016/S2352-3018(18)30296-0. [Epub ahead of print]

PMID:
30555051
28.

Postpartum HIV care continuum outcomes in the southeastern USA.

Chen JS, Pence BW, Rahangdale L, Patterson KB, Farel CE, Durr AL, Antono AC, Zakharova O, Eron JJ, Napravnik S.

AIDS. 2019 Mar 15;33(4):637-644. doi: 10.1097/QAD.0000000000002094.

PMID:
30531320
29.

Prediction of HIV Transmission Cluster Growth With Statewide Surveillance Data.

Billock RM, Powers KA, Pasquale DK, Samoff E, Mobley VL, Miller WC, Eron JJ, Dennis AM.

J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):152-159. doi: 10.1097/QAI.0000000000001905.

PMID:
30422907
30.

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ.

PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov.

31.

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART.

Riddler SA, Zheng L, Durand CM, Ritz J, Koup RA, Ledgerwood J, Bailer RT, Koletar SL, Eron JJ, Keefer MC, Macatangay BJC, Cyktor JC, Mellors JW; AIDS Clinical Trials Group A5342 Protocol Team .

Open Forum Infect Dis. 2018 Oct 20;5(10):ofy242. doi: 10.1093/ofid/ofy242. eCollection 2018 Oct.

32.

Cumulative Human Immunodeficiency Viremia, Antiretroviral Therapy, and Incident Myocardial Infarction.

Delaney JA, Nance RM, Whitney BM, Crane HM, Williams-Nguyen J, Feinstein MJ, Kaplan RC, Hanna DB, Budoff MJ, Drozd DR, Burkholder G, Mugavero MJ, Mathews WC, Moore RD, Eron JJ, Hunt PW, Geng E, Saag MS, Kitahata MM, Heckbert SR.

Epidemiology. 2019 Jan;30(1):69-74. doi: 10.1097/EDE.0000000000000930.

PMID:
30273188
33.

HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Sung JA, Patel S, Clohosey ML, Roesch L, Tripic T, Kuruc JD, Archin N, Hanley PJ, Cruz CR, Goonetilleke N, Eron JJ, Rooney CM, Gay CL, Bollard CM, Margolis DM.

Mol Ther. 2018 Oct 3;26(10):2496-2506. doi: 10.1016/j.ymthe.2018.08.015. Epub 2018 Sep 21.

34.

Adaptation of spatio-temporal convergent properties in central vestibular neurons in monkeys.

Eron JN, Ogorodnikov D, Horn AKE, Yakushin SB.

Physiol Rep. 2018 Sep;6(17):e13750. doi: 10.14814/phy2.13750.

35.

Prevalence and Transmission Dynamics of HIV-1 Transmitted Drug Resistance in a Southeastern Cohort.

Levintow SN, Okeke NL, Hué S, Mkumba L, Virkud A, Napravnik S, Sebastian J, Miller WC, Eron JJ, Dennis AM.

Open Forum Infect Dis. 2018 Jul 20;5(8):ofy178. doi: 10.1093/ofid/ofy178. eCollection 2018 Aug.

36.

Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation.

Davy-Mendez T, Napravnik S, Zakharova O, Kuruc J, Gay C, Hicks CB, Mcgee KS, Eron JJ.

J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):510-518. doi: 10.1097/QAI.0000000000001843.

PMID:
30142143
37.

HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study.

Nance RM, Delaney JAC, Simoni JM, Wilson IB, Mayer KH, Whitney BM, Aunon FM, Safren SA, Mugavero MJ, Mathews WC, Christopoulos KA, Eron JJ, Napravnik S, Moore RD, Rodriguez B, Lau B, Fredericksen RJ, Saag MS, Kitahata MM, Crane HM.

Ann Intern Med. 2018 Sep 18;169(6):376-384. doi: 10.7326/M17-2242. Epub 2018 Aug 21.

38.

New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations.

Davy-Mendez T, Eron JJ, Brunet L, Zakharova O, Dennis AM, Napravnik S.

AIDS. 2018 Nov 13;32(17):2593-2603. doi: 10.1097/QAD.0000000000001990.

PMID:
30134298
39.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ Jr, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA.

JAMA. 2018 Jul 24;320(4):379-396. doi: 10.1001/jama.2018.8431.

40.

Brief Report: Reduced Use of Illicit Substances, Even Without Abstinence, Is Associated With Improved Depressive Symptoms Among People Living With HIV.

Delaney JA, Nance RM, Whitney BM, Altice FL, Dong X, Trejo MEP, Matsuzaki M, Taxman FS, Chander G, Kuo I, Fredericksen R, Strand LN, Eron JJ, Geng E, Kitahata MM, Mathews WC, Mayer K, Moore RD, Saag MS, Springer S, Chandler R, Kahana S, Crane HM.

J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):283-287. doi: 10.1097/QAI.0000000000001803.

PMID:
30036277
41.

Using Primer-ID Deep Sequencing to Detect Recent Human Immunodeficiency Virus Type 1 Infection.

Dennis AM, Zhou S, Sellers CJ, Learner E, Potempa M, Cohen MS, Miller WC, Eron JJ, Swanstrom R.

J Infect Dis. 2018 Oct 20;218(11):1777-1782. doi: 10.1093/infdis/jiy426.

PMID:
30010965
42.

Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors.

Nance RM, Crane HM, Ritchings C, Rosenblatt L, Budoff M, Heckbert SR, Drozd DR, Mathews WC, Geng E, Hunt PW, Feinstein MJ, Moore RD, Hsue P, Eron JJ, Burkholder GA, Rodriguez B, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):916-921. doi: 10.1089/AID.2018.0053. Epub 2018 Aug 21.

PMID:
29984593
43.

Comparing neighborhood and state contexts for women living with and without HIV: understanding the Southern HIV epidemic.

Ludema C, Edmonds A, Cole SR, Eron JJ Jr, Adedimeji AA, Cohen J, Cohen MH, Kassaye S, Konkle-Parker DJ, Metsch LR, Wingood GM, Wilson TE, Adimora AA.

AIDS Care. 2018 Nov;30(11):1360-1367. doi: 10.1080/09540121.2018.1492696. Epub 2018 Jul 1.

PMID:
29962235
44.

Leveraging Phylogenetics to Understand HIV Transmission and Partner Notification Networks.

Pasquale DK, Doherty IA, Sampson LA, Hué S, Leone PA, Sebastian J, Ledford SL, Eron JJ, Miller WC, Dennis AM.

J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):367-375. doi: 10.1097/QAI.0000000000001695.

45.

Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy.

Lee JS, Cole SR, Achenbach CJ, Dittmer DP, Richardson DB, Miller WC, Mathews C, Althoff KN, Moore RD, Eron JJ Jr; Center for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS).

PLoS One. 2018 Jun 5;13(6):e0197665. doi: 10.1371/journal.pone.0197665. eCollection 2018.

46.

T cells establish and maintain CNS viral infection in HIV-infected humanized mice.

Honeycutt JB, Liao B, Nixon CC, Cleary RA, Thayer WO, Birath SL, Swanson MD, Sheridan P, Zakharova O, Prince F, Kuruc J, Gay CL, Evans C, Eron JJ, Wahl A, Garcia JV.

J Clin Invest. 2018 Jul 2;128(7):2862-2876. doi: 10.1172/JCI98968. Epub 2018 Jun 4.

47.

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.

Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, Riddler SA, Sax PE, Daar ES, Morse GD, Acosta EP, Ritchie MD.

Pharmacogenet Genomics. 2018 Jul;28(7):179-187. doi: 10.1097/FPC.0000000000000341.

48.

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.

Eron JJ, Orkin C, Gallant J, Molina JM, Negredo E, Antinori A, Mills A, Reynes J, Van Landuyt E, Lathouwers E, Hufkens V, Jezorwski J, Vanveggel S, Opsomer M; AMBER study group.

AIDS. 2018 Jul 17;32(11):1431-1442. doi: 10.1097/QAD.0000000000001817.

49.

Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.

Menezes P, Mollan K, Hoffman E, Xie Z, Wills J, Marcus C, Rublein J, Hudgens M, Eron JJ Jr.

AIDS Res Hum Retroviruses. 2018 Jun;34(6):481-485. doi: 10.1089/AID.2016.0311. Epub 2018 May 2.

50.

Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART.

Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, Louie A, Phung N, Eron JJ, Hogg E, Macatangay BJC, Hensel C, Fletcher CV, Mellors JW, McMahon DK; A5321 Team.

J Infect Dis. 2018 Jun 20;218(2):234-238. doi: 10.1093/infdis/jiy011.

Supplemental Content

Support Center